POZ - Treatment News : Extended-Release Viramune Begins Study
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2008

Web Exclusives

Looking Back, Moving Forward: Reflections on USCA

NAPWA Testifies Before Congress

Renewing the Denver Principles

» More

Most Talked About

A 'Functional' Cure for HIV? (17)

Just Found Out? A POZ.com Guide for HIV Rookies (14)

Only Took Me 23 Years... (blog) (14)

The State of AIDS in Puerto Rico (13)

Politicians Urge Bush for Final Repeal of HIV Travel Ban (11)

TGI Friday’s Fined for Firing HIV-Positive Employee (8)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

February 12, 2008

Extended-Release Viramune Begins Study

Boehringer Ingelheim, the maker of Viramune (nevirapine), announced that it has begun enrolling participants in a clinical trial of an extended-release formulation of the drug for once-daily dosing. The current formulation of Viramune is approved for use in the U.S. at a dose of 200 mg twice a day. The dose being studied is 400 mg once a day.

The new formulation will be tested in the VERXVE study, which will pair it with Truvada (tenofovir and emtricitabine), and compare it to the current twice-a-day formulation of Viramune, also paired with Truvada. The study will enroll 1,000 patients in 18 countries, who’ve never taken antiretroviral therapy before.

The study will enroll patients throughout 2008, and results are expected in 2010.


Scroll down to comment on this story.

emailrssprint


Name: (2-50 characters)
Email: (will not show)
City: (optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

  comments 1 - 6 (of 6 total)    

tim, , 2008-02-19 09:22:39
Interesting that I've been on this once a day combo since Nov 2006. And the drug company is just getting around to studying this. Am I missing something?

Adam, , 2008-02-18 21:24:51
I have taken viramune once daily since April 2005. Viral still undectable

ken, , 2008-02-17 20:04:20
I take this cocktail,no side effects,counts are the best since the early 90's,so I'm very excited to see the outcome

Lane Kelly-King, Atlanta, 2008-02-17 18:15:10
I have been taking once daily virumune for about 2 mos.I just have my labs done last fri. I do combivir as part of my cocktail. I was on it before then took a 3 yr holiday and started back on it about a yr ago. They are all still working. I have had no problems with the dosage change whatsoever.

Rick, HOUSTON, 2008-02-13 13:23:43
Correction to my posting. I have been taking "once a-day" Travada/Viramune since June '07, not December as stated.

Rick, HOUSTON, 2008-02-13 13:06:34
Interesting article. I have been doing "once a-day" since starting on Travada/Viramune in Dec '07. No problems!!

comments 1 - 6 (of 6 total)    


[Go to top]

Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Have you ever been tested for TB?
Yes
No

Monthly Poll
Question: Do you think the new American president will effectively address HIV/AIDS issues during his first 100 days?
Yes
No
I don't know

Surveys
Tell us about your travel experiences.

Tell us about your pets.

more surveys  
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy